Cite
Noninvasive Assessment of HER2 Expression Status in Gastric Cancer Using 18F-FDG Positron Emission Tomography/Computed Tomography-Based Radiomics: A Pilot Study.
MLA
Jiang, Xiaojing, et al. “Noninvasive Assessment of HER2 Expression Status in Gastric Cancer Using 18F-FDG Positron Emission Tomography/Computed Tomography-Based Radiomics: A Pilot Study.” Cancer Biotherapy & Radiopharmaceuticals, vol. 39, no. 3, Apr. 2024, pp. 169–77. EBSCOhost, https://doi.org/10.1089/cbr.2023.0162.
APA
Jiang, X., Li, T., Wang, J., Zhang, Z., Chen, X., Zhang, J., & Zhao, X. (2024). Noninvasive Assessment of HER2 Expression Status in Gastric Cancer Using 18F-FDG Positron Emission Tomography/Computed Tomography-Based Radiomics: A Pilot Study. Cancer Biotherapy & Radiopharmaceuticals, 39(3), 169–177. https://doi.org/10.1089/cbr.2023.0162
Chicago
Jiang, Xiaojing, Tianyue Li, Jianfang Wang, Zhaoqi Zhang, Xiaolin Chen, Jingmian Zhang, and Xinming Zhao. 2024. “Noninvasive Assessment of HER2 Expression Status in Gastric Cancer Using 18F-FDG Positron Emission Tomography/Computed Tomography-Based Radiomics: A Pilot Study.” Cancer Biotherapy & Radiopharmaceuticals 39 (3): 169–77. doi:10.1089/cbr.2023.0162.